Balaji Prasad
Stock Analyst at Barclays
(2.83)
# 1,573
Out of 5,170 analysts
147
Total ratings
49.19%
Success rate
4.74%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $4.86 | +414.40% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $12.34 | -10.86% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $22.57 | +6.34% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $13.50 | -33.33% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $181.80 | +10.01% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $25.12 | -24.36% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $66.75 | -10.11% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $115.99 | +110.36% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $6.27 | +282.78% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $52.38 | -58.00% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $579.85 | -10.32% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $29.44 | -11.68% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $210.49 | -23.99% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.14 | +20.23% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $3.58 | +402.79% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $4.37 | +128.83% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.61 | +334.78% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $4.86
Upside: +414.40%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $12.34
Upside: -10.86%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $22.57
Upside: +6.34%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $13.50
Upside: -33.33%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $181.80
Upside: +10.01%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $25.12
Upside: -24.36%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $66.75
Upside: -10.11%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $115.99
Upside: +110.36%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $6.27
Upside: +282.78%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $52.38
Upside: -58.00%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $579.85
Upside: -10.32%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $29.44
Upside: -11.68%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $210.49
Upside: -23.99%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.14
Upside: +20.23%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $3.58
Upside: +402.79%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $4.37
Upside: +128.83%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.61
Upside: +334.78%